V Najfeld, N Wisch, J Mascarenhas, L Issa… - Cancer Genetics, 2011 - Elsevier A 65-year-old patient with a high hemoglobin and hematocrit was treated for 14 months with therapeutic phlebotomy when cytogenetics of bone marrow revealed 100% cells with the Ph chromosome and 45% of the Ph+ cells contained trisomy 8. Treatment with tyrosine ... Related articles - All 3 versions
MJ Kluk… - Diagnostic Molecular Pathology in Practice, 2011 - Springer The patient was a 50-year-old man with a history of hypertension and hyperlipidemia who presented to his primary care physician for malaise, fatigue, and pain in the left upper quadrant. An enlarged spleen was identified on physical exam and initial laboratory anal- ysis of the peripheral ...
[HTML] from hematologylibrary.orgEA Nelson, SR Walker, E Weisberg… - …, 2011 - bloodjournal.hematologylibrary.org The transcription factor STAT5 is an essential mediator of the pathogenesis of chronic myelogenous leukemia (CML). In CML, the BCR/ABL fusion kinase causes the constitutive activation of STAT5, thereby driving the expression of genes promoting survival. BCR/ABL kinase ... Cited by 3 - Related articles - All 4 versions
L Sellner, MR Veldwijk… - Leukemia & …, 2011 - informahealthcare.com Gene transfer into chronic myelogenous leukemia (CML) cells may become of relevance for overcoming therapy resistance. Single-stranded pseudotyped adeno-associated viruses of serotypes 2/1 to 2/6 (ssAAV2/1–ssAAV2/6) were screened on human CML cell lines and primary ... Related articles - All 3 versions
[PDF] from hematologylibrary.orgH Makishima, AM Jankowska… - …, 2011 - bloodjournal.hematologylibrary.org Progression of chronic myelogenous leukemia (CML) to accelerated (AP) and blast phase (BP) is because of secondary molecular events, as well as additional cytogenetic abnormalities. On the basis of the detection of JAK2, CBL, CBLB, TET2, ASXL1, and ... Cited by 3 - Related articles - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
